31.84 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||30.00 x 900|
|Ask||70.00 x 1400|
|Day's Range||31.50 - 32.36|
|52 Week Range||28.54 - 46.59|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||25.07|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do b...
Anika (ANIK) delivered earnings and revenue surprises of 50.00% and 2.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Bedford, Massachusetts-based company said it had net income of 54 cents. The medical technology company posted revenue of $27 million in the period. For the year, the company ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anika Therapeutics, Inc. (NASDAQ:ANIK), which has zero-debt on its balanceRead More...
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika Therapeutics, Inc. (NASDAQ:ANIK), which is in the medical equipment business, and is based in United States, saw a double-digit share price rise of over 10% in the past couple Read More...
According to the GuruFocus All-in-One Screener, the following stocks are trading at a discount and have positive three- to five-year future earnings estimates. Warning! GuruFocus has detected 3 Warning Signs with VIA. The discounted cash flow calculator gives the stock a fair value of $52.04 per share, suggesting it has a 44% margin of safety.
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Anika Therapeutics, Inc. (NASDAQ:ANIK). Is Anika Therapeutics, Inc. (NASDAQ:ANIK) worth […]
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Read More...
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Anika Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week ...
Anika (ANIK) delivered earnings and revenue surprises of 55.88% and -1.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Bedford, Massachusetts-based company said it had net income of 53 cents per share. The medical technology company posted revenue of $26.8 million in the period. Anika shares have decreased 27 percent ...